Compare Merck & Co., Inc. (MRK) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Taskus Inc — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Taskus Inc trades at $7.59 (market cap $700.49M). The key difference: Merck & Co., Inc. is far larger — about 522.9× Taskus Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| MRK | TASK | |
|---|---|---|
Market Cap | $366.28B | $700.49M |
Sector | Health | Technology |
52-Week High | $156.43 | $18.03 |
52-Week Low | $77.60 | $4.57 |
Enterprise Value | $413.04B | $1.07B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
TaskUs (TASK) trades at $7.65, down 3.29% today, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income of $102.28M, yielding attractive valuation ratios including a P/E of 6.59 and P/S of 0.58. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI Services growth.
The stock presents value opportunity with discounted multiples and analyst consensus target of $8.00 (4.6% upside). Risks include client concentration and competitive pressures in digital services. Institutional interest remains positive with Dimensional Fund increasing holdings by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
